Core Viewpoint - In 2025, Shandong Wohua Pharmaceutical reported a revenue of 817 million yuan, a year-on-year increase of 6.96%, and a net profit of 96 million yuan, a staggering increase of 162.93%. However, the annual report reveals several risk signals, including high sales expenses, unusual inter-subsidiary fund transfers, and governance challenges due to the company's "no actual controller" status [1][7]. Group 1: High Sales Expenses and Fund Transfers - Wohua Pharmaceutical maintained a gross margin of 75.38% in 2025, with its core cardiovascular drugs achieving a gross margin of 83.43%, highlighting the competitiveness of its "exclusive + medical insurance" product matrix [2][8]. - The company incurred sales expenses of approximately 407 million yuan, accounting for nearly 50% of its revenue, raising concerns about compliance risks amid heightened regulatory scrutiny on marketing expenses [2][8]. - The company provided 247 million yuan in loans to its loss-making subsidiary, Liaoning Wohua Kangchen, while its profitable subsidiary, Jiangxi Wohua Jishun, earned 18.54 million yuan, questioning the commercial rationale and safety of such financial support [2][8]. Group 2: Governance Risks from "No Actual Controller" Status - In November 2025, Wohua Pharmaceutical entered a "no actual controller" status due to a court ruling, significantly impacting its governance and decision-making mechanisms [3][10]. - The annual report's disclosure regarding this change was minimal, with critical information placed in less prominent sections, increasing the difficulty for investors to access and understand key governance risks [3][10]. - Compliance experts noted that the reasons and implications of the "no actual controller" status should have been clearly stated in the relevant sections of the report, as this situation could lead to decision-making deadlocks [3][10]. Group 3: Environmental and Climate Disclosure Issues - Wohua Pharmaceutical's environmental performance, particularly regarding wastewater and air emissions, was inadequately reported, with key data not directly listed but linked to external platforms, complicating information access for investors [4][11]. - The company failed to provide any climate-related disclosures, such as risk identification or carbon emission accounting, reflecting a lack of maturity in ESG data management among traditional pharmaceutical companies [5][11]. - The reliance on "link-based disclosure" was criticized as merely meeting formal compliance requirements without providing substantial transparency [4][11]. Conclusion - Wohua Pharmaceutical's 2025 annual report presents a picture of impressive performance but raises concerns regarding governance, compliance, and transparency. As regulatory scrutiny intensifies, the company must address these issues to enhance its governance and disclosure practices [6][12].